Microdystrophin nucleic acid gene therapy constructs and uses thereof

Inventors

Qiao, Chunping • McDougald, Devin • Liu, Ye • Danos, Olivier

Assignees

Regenxbio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12752020-B2

Patent

Publication Date

2026-10-06

Expiration Date


Abstract

Provided are gene constructs that encode a microdystrophin protein for use in gene therapy. The microdystrophin gene constructs and expression cassettes were engineered for improved therapy with respect to efficacy, potency and safety to the subject when expressed by a viral vector in muscle cells and/or CNS cells.

Core Innovation

The invention provides microdystrophin gene-therapy constructs, RGX-DYS expression cassettes, plasmids, and host cells comprising nucleic acids encoding microdystrophin proteins with SEQ ID NO: 79 or SEQ ID NO: 1, or comprising SEQ ID NO: 53. The encoded proteins comprise an ABD, hinge, selected spectrin-repeat, cysteine-rich, and optional C-terminal domains. The expression cassettes incorporate muscle-specific regulatory elements such as the SPc5-12 promoter, a VH4 intron, polyadenylation sequences, and flanking adeno-associated virus inverted terminal repeats.

The microdystrophin vectors demonstrate improved muscle force and grip strength while restoring dystrophin-associated proteins including syntrophin and beta-dystroglycan in mdx mice. Vector transduction reduces elevated Pax7 mRNA and regeneration markers in satellite cells, consistent with improved muscle regeneration. Furthermore, codon optimization and CpG depletion support sustained expression, proper splicing, and reduced immune recognition across muscle and CNS targets.

Claims Coverage

The independent claims cover seven inventive features directed to nucleic acids encoding specified microdystrophin proteins, plasmids and host cells containing such nucleic acids, and nucleic acids, plasmids, and host cells comprising SEQ ID NO: 53.

Nucleic acid encoding microdystrophin comprising SEQ ID NO: 79

A claim element covers a nucleic acid comprising a nucleotide sequence encoding a microdystrophin protein comprising the amino acid sequence of SEQ ID NO: 79, or the reverse complement thereof.

Nucleic acid encoding microdystrophin comprising SEQ ID NO: 1

A claim element covers a nucleic acid comprising a nucleotide sequence encoding a microdystrophin protein comprising the amino acid sequence of SEQ ID NO: 1, or the reverse complement thereof.

Plasmid containing nucleic acid encoding microdystrophin comprising SEQ ID NO: 1

A claim element covers a plasmid comprising a nucleic acid comprising a nucleotide sequence encoding a microdystrophin protein comprising the amino acid sequence of SEQ ID NO: 1, or the reverse complement of the nucleotide sequence.

Host cell containing plasmid encoding microdystrophin comprising SEQ ID NO: 1

A claim element covers a host cell comprising a plasmid comprising a nucleic acid comprising a nucleotide sequence encoding a microdystrophin protein comprising the amino acid sequence of SEQ ID NO: 1, or the reverse complement of the nucleotide sequence.

Nucleic acid comprising SEQ ID NO: 53

A claim element covers a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 53.

Plasmid containing nucleic acid comprising SEQ ID NO: 53

A claim element covers a plasmid comprising a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 53.

Host cell containing plasmid with nucleic acid comprising SEQ ID NO: 53

A claim element covers a host cell comprising a plasmid comprising a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 53.

Together, the independent claims cover specified microdystrophin-encoding nucleic acids and their plasmid and host-cell forms, as well as nucleic acid, plasmid, and host-cell subject matter comprising SEQ ID NO: 53.

Stated Advantages

C-terminal binding sites may recruit dystrophin-associated proteins and support cardiac protection.

Microdystrophin vectors improve muscle strength, grip strength, and muscle force in mdx mice.

Microdystrophin vectors restore dystrophin-associated proteins, with RGX-DYS1 demonstrating strong syntrophin and beta-dystroglycan restoration.

Treatment reduces Pax7 mRNA and elevated satellite-cell markers associated with dystrophic muscle regeneration.

Codon optimization and CpG depletion reduce immune recognition and support prolonged, sustained expression.

The VH4 intron enhances proper splicing and microdystrophin expression.

Documented Applications

AAV expression cassettes and vectors are proposed for dystrophinopathy treatment, including Duchenne muscular dystrophy and Becker muscular dystrophy.

Experimental evaluation, assays, and treatment with microdystrophin vectors in mdx mice, including assessment of microdystrophin expression and associated biological effects in mdx muscle.

Recombinant adeno-associated virus vectors configured with muscle-specific regulatory elements for microdystrophin expression.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.